Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthcare Sector Analysis

UpdatedSep 17, 2025
DataAggregated Company Financials
Companies1363
  • 7D-1.7%
  • 3M3.2%
  • 1Y-12.4%
  • YTD-1.7%

Over the last 7 days, the Healthcare industry has dropped 1.7%, driven by declines in Boston Scientific and Intuitive Surgical of 8.4% and 7.1%, respectively. However, the industry is down 12% over the past year. Earnings are forecast to grow by 15% annually.

Sector Valuation and Performance

Has the U.S. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 17 Sep 2025US$5.7tUS$3.1tUS$137.5b23.8x41.2x1.8x
Fri, 15 Aug 2025US$5.6tUS$3.1tUS$136.9b23.4x40.5x1.8x
Sun, 13 Jul 2025US$5.5tUS$3.0tUS$127.9b24x43.3x1.8x
Tue, 10 Jun 2025US$5.5tUS$3.0tUS$127.2b23.8x43.2x1.8x
Thu, 08 May 2025US$5.4tUS$3.0tUS$127.1b25x42.7x1.8x
Sat, 05 Apr 2025US$5.5tUS$2.6tUS$82.1b24.7x67x2.1x
Mon, 03 Mar 2025US$5.9tUS$2.6tUS$79.3b27.5x74x2.2x
Wed, 29 Jan 2025US$6.2tUS$2.9tUS$85.5b27.9x72x2.1x
Fri, 27 Dec 2024US$5.9tUS$2.9tUS$78.3b27.6x74.8x2x
Sun, 24 Nov 2024US$6.0tUS$2.9tUS$77.3b28.2x78.1x2.1x
Tue, 22 Oct 2024US$6.2tUS$2.8tUS$58.7b32.1x106.4x2.2x
Thu, 19 Sep 2024US$6.3tUS$2.8tUS$60.2b31.1x104.5x2.2x
Sat, 17 Aug 2024US$6.1tUS$2.8tUS$56.1b32.8x109.5x2.2x
Mon, 15 Jul 2024US$6.3tUS$2.8tUS$62.2b31.2x101.7x2.2x
Wed, 12 Jun 2024US$6.2tUS$2.8tUS$63.6b30.2x97.9x2.2x
Fri, 10 May 2024US$6.1tUS$2.8tUS$62.9b30.6x96.7x2.2x
Sun, 07 Apr 2024US$6.2tUS$2.8tUS$84.1b32.4x73.2x2.2x
Tue, 05 Mar 2024US$6.3tUS$2.8tUS$85.0b31x74x2.3x
Thu, 01 Feb 2024US$6.4tUS$2.8tUS$80.6b31.6x79.2x2.3x
Sat, 30 Dec 2023US$6.2tUS$2.8tUS$91.5b32.6x68.2x2.2x
Mon, 27 Nov 2023US$5.9tUS$2.8tUS$91.4b28.6x64.4x2.1x
Wed, 25 Oct 2023US$5.7tUS$2.8tUS$99.6b24.8x57.3x2x
Fri, 22 Sep 2023US$5.9tUS$2.8tUS$98.6b27.4x60.1x2.1x
Sun, 20 Aug 2023US$6.1tUS$2.8tUS$99.2b27.9x61.4x2.2x
Tue, 18 Jul 2023US$6.0tUS$2.7tUS$110.9b26.1x54x2.2x
Thu, 15 Jun 2023US$6.0tUS$2.7tUS$110.1b25.6x54.1x2.2x
Sat, 13 May 2023US$6.0tUS$2.7tUS$114.6b24.7x52.3x2.2x
Mon, 10 Apr 2023US$5.9tUS$2.5tUS$124.4b24.6x47.6x2.4x
Wed, 08 Mar 2023US$5.7tUS$2.5tUS$122.3b24.8x46.5x2.3x
Fri, 03 Feb 2023US$6.0tUS$2.5tUS$135.3b23.8x44.5x2.4x
Sun, 01 Jan 2023US$6.1tUS$2.5tUS$135.6b23.1x44.7x2.5x
Tue, 29 Nov 2022US$6.0tUS$2.4tUS$133.6b23.8x44.8x2.5x
Thu, 27 Oct 2022US$5.8tUS$2.4tUS$157.4b22.8x37.1x2.4x
Sat, 24 Sep 2022US$5.5tUS$2.4tUS$155.9b20.7x35.4x2.3x
Price to Earnings Ratio

35.4x


Total Market Cap: US$5.5tTotal Earnings: US$155.9bTotal Revenue: US$2.4tTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthcare Sector Price to Earnings3Y Average 64.7x202320242025
Current Industry PE
  • Investors are pessimistic on the American Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 41.2x which is lower than its 3-year average PE of 64.7x.
  • The 3-year average PS ratio of 2.2x is higher than the industry's current PS ratio of 1.8x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 4.1% per year over the last three years.
  • Meanwhile revenues for these companies have grown 8.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare sector?

US Market1.62%
Healthcare-1.68%
Life Sciences-0.18%
Pharma-0.54%
Healthcare Services-1.74%
Healthtech-2.12%
Biotech-2.17%
Medical Equipment-3.35%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 57.4x.
    • Analysts expect its future annual earnings growth (12.8%) to be largely in line with prior year's earnings growth.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 25% over the next 5 years.
  • However this is lower than its past earnings growth rate of 65% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 12% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LLY Eli LillyUS$764.711.9%
+US$12.7b		-15.6%PE49.7x
ABBV AbbVieUS$216.262.8%
+US$10.3b		11.8%PE102.6x
CVS CVS HealthUS$73.482.4%
+US$2.2b		27.1%PE20.6x
REGN Regeneron PharmaceuticalsUS$575.063.3%
+US$1.9b		-49.9%PE13.4x
ABT Abbott LaboratoriesUS$132.760.6%
+US$1.4b		12.4%PE16.6x

Latest News

HIMS
US$50.89
Hims & Hers Health
7D
6.5%
1Y
216.1%
ABBV
US$216.26
AbbVie
7D
2.8%
1Y
11.8%
UNH
US$339.78
UnitedHealth Group
7D
-2.3%
1Y
-41.2%
MRK
US$81.09
Merck
7D
-4.2%
1Y
-31.4%
ABT
US$132.76
Abbott Laboratories
7D
0.6%
1Y
12.4%

There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings

Sep 15
There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
TEM
US$87.04
Tempus AI
7D
7.4%
1Y
76.8%

Expanding Genomic Testing And AI Will Build Lasting Healthcare Value

Tempus AI’s consensus future P/E and discount rate held steady with minimal movement, supporting only a slight upward revision in fair value from $72.73 to $73.45. What's in the News Tempus AI received FDA 510(k) clearance for its updated Tempus Pixel, an AI-powered cardiac imaging platform, which now enables generation of T1 and T2 inline maps for enhanced cardiac MR image analysis, supporting more precise and efficient diagnostics.
RVMD
US$44.70
Revolution Medicines
7D
9.2%
1Y
2.1%
ISRG
US$434.50
Intuitive Surgical
7D
-7.1%
1Y
-10.1%
PFE
US$23.90
Pfizer
7D
-3.3%
1Y
-19.9%
REGN
US$575.06
Regeneron Pharmaceuticals
7D
3.3%
1Y
-49.9%
SYK
US$376.62
Stryker
7D
-4.1%
1Y
3.5%
LLY
US$764.71
Eli Lilly
7D
1.9%
1Y
-15.6%
AMGN
US$273.09
Amgen
7D
-2.5%
1Y
-17.9%
GILD
US$110.86
Gilead Sciences
7D
-4.2%
1Y
33.5%
BSX
US$98.98
Boston Scientific
7D
-8.4%
1Y
19.9%
CVS
US$73.48
CVS Health
7D
2.4%
1Y
27.1%

Digital Health Transformation And Integrated Care Will Expand Reach

Despite ongoing external risks and policy uncertainty, analysts remain constructive on CVS Health, citing strong recent execution, conservative guidance with potential for upside, and compelling valuation, resulting in the consensus price target holding steady at $81.57. Analyst Commentary Bullish analysts cite strong recent execution and early signs that fixes in the healthcare benefits segment are proving effective, supporting above-consensus earnings growth projections.